In the phase II FAKTION trial, patients with endocrine-resistant advanced ER+/HER2-breast cancer were randomized to receive fulvestrant and capiversertib versus fulvestrant and placebo (Jones et al., 2020). The gene discussed is ERBB2; the disease is breast cancer.